T-cell lymphoma (TCL) is an uncommon subtype accounting for approximately 15% of all cases of non-Hodgkin lymphoma in the United States (LRF, 2022). Compared with its B-cell counterpart, TCL has a poor prognosis and is associated with a 5-year survival rate of less than 20%. The clinical and pathologic presentations of TCL are varied and often nonspecific, making diagnosis and treatment challenging (Salem et al, 2021). In this activity, Aaron Goodman, MD, will update clinicians on evidence-based criteria for differential diagnosis, appraise efficacy and safety data to guide therapeutic selection for newly diagnosed and relapsed/refractory disease, and highlight strategies for optimizing treatment tolerability and improving outcomes in patients with TCL.